InvestorsHub Logo
Followers 617
Posts 93690
Boards Moderated 8
Alias Born 11/01/2006

Re: None

Thursday, 09/17/2020 9:53:31 AM

Thursday, September 17, 2020 9:53:31 AM

Post# of 58494
Management notes that the Company also announced a 43% increase in total outstanding GenTech common shares during the three months ended July 31, 2020, which represents the overall equity cost of the Sinfit acquisition.

However, the Company urges shareholders to view this information in context


The context is this...

As of 07/31/19, the number of shares outstanding of our Common Stock was: 385,563,721

Currently, it's 3,058,058,634.

Cash up 2,580% on a sequential quarterly basis, and up over 6,700% annually

We know where the cash comes from. It's not from sales.

Note that, in simple terms, our total liabilities held steady from April to July

True. All their liabilities were incurred prior to April. $3,055,470!

Now, to my original suggestion of releasing current annual revenues for 2010 to compare with 2019's, Lovatt states.....

And we continue to project a potential for over $3 million in sales in 2021. What about 2020?

Recall that revs from 2019 were $2.5. So the "projected" numbers are only slightly better than from two years prior.

I expect nothing but a positive slant to everything an OTC CEO puts out but people need to look closer at what a biased source releases in a pr, which is only meant to instill confidence and enthusiasm.

You can lead a horse to water. But you can't make him get down on one knee and do an Al Jolson impression!